English  |  正體中文  |  简体中文  |  总笔数 :2853537  
造访人次 :  45248812    在线人数 :  896
教育部委托研究计画      计画执行:国立台湾大学图书馆
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
关于TAIR

浏览

消息

著作权

相关连结

"楊志新"的相关文件

回到依作者浏览
依题名排序 依日期排序

显示项目 61-70 / 209 (共21页)
<< < 2 3 4 5 6 7 8 9 10 11 > >>
每页显示[10|25|50]项目

机构 日期 题名 作者
國立臺灣大學 2015 Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene Wu, Hsu; Shih, Jin-Yuan; Yang, James Chih-Hsin; 楊志新; 施金元
國立臺灣大學 2015 Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC) Passaro, A.; Yang, J. C.; Ahn, M.; Dickgreber, N. J.; Halmos, B.; Hirsh, V.; Hochmair, M. J.; Levy, B. P.; de Marinis, F.; Mok, T.; O'Byrne, K.; Okamoto, I.; Schuler, M.; Sebastian, M.; Shah, R.; Tan, E.; Yamamoto, N.; Maerten, A.; Wind, S.; Carbone, D. P.; 楊志新
國立臺灣大學 2015 Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC Mok, T.; Saijo, N.; Thongprasert, S.; Yang, J. C. -H.; Wu, Y. -L.; Young, H.; Haddad, V.; Jiang, H.; Fukuoka, M.; 楊志新
國立臺灣大學 2015 AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer Jaenne, Pasi A.; Yang, James Chih-Hsin; Kim, Dong-Wan; Planchard, David; Ohe, Yuichiro; Ramalingam, Suresh S.; Ahn, Myung-Ju; Kim, Sang-We; Su, Wu-Chou; Horn, Leora; Haggstrom, Daniel; Felip, Enriqueta; Kim, Joo-Hang; Frewer, Paul; Cantarini, Mireille; Brown, Kathryn H.; Dickinson, Paul A.; Ghiorghiu, Serban; Ranson, Malcolm; 楊志新
國立臺灣大學 2015 AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort. Ramalingam, Suresh S.; Yang, James Chih-Hsin; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Rukazenkov, Yuri; Frewer, Paul; Cantarini, Mireille; Ghiorghiu, Serban; Janne, Pasi A.; 楊志新
國立臺灣大學 2015 Maintenance with Gefitinib/Pemetrexed (G/P) or P After Induction P/Platinum for Stage IV Lung Adenocarcinoma with No Sensitizing EGFR Mutation Tsai, Chun-Ming; Lai, Chun-Liang; Chiu, Chao-Hua; Hsia, Te-Chun; Chen, Chen-Hsin; Chang, Gee-Chen; Shih, Jin-Yuan; Ho, Ching-Liang; Chen, Yuh-Min; Yang, James Chih-Hsin; 楊志新; 施金元; 陳珍信
國立臺灣大學 2015 Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged >= 65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) Wu, Y. -L.; Sequist, L. V.; Geater, S. L.; Orlov, S.; Lee, K. H.; Tsai, C. -M.; Kato, T.; Kiura, K.; Barrios, C. H.; Schuler, M.; Hirsh, V.; Yamamoto, N.; O'Byrne, K.; Mok, T.; Massey, D.; Maerten, A.; Yang, J. C. -H.; 楊志新
國立臺灣大學 2015 TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib in EGFR-Mutant NSCLC Camidge, Ross; Cappuzzo, Federico; Go, Jowell; Isaacson, Jeffrey; Litten, Jason; Park, Keunchil; Spigel, David R.; Spira, Alexander; Vergnenegre, Alain; Wolf, Juergen; Yang, James Chih-Hsin; Mok, Tony; 楊志新
國立臺灣大學 2015 Antitumor Activity of Tepotinib plus Gefitinib in Asian Patients with Met plus EGFRm plus NSCLC Kim, Dong-Wan; Soo, Ross; Yang, James Chih-Hsin; Park, Keunchil; Stammberger, Uz; Xiong, Huiiling; Ihling, Christian; Wu, Yi-Long; 楊志新
國立臺灣大學 2014 Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations Chen, Yen-Fu; Hsieh, Min-Shu; Wu, Shang-Gin; Chang, Yih-Leong; Shih, Jin-Yuan; Liu, Yi-Nan; Tsai, Meng-Feng; Tsai, Tzu-Hsiu; Yu, Chong-Jen; Yang, James Chih-Hsin; Yang, Pan-Chyr; 楊志新; 張逸良; 楊泮池; 余忠仁; 謝明書; 吳尚俊; 陳瑛芳; 蔡子修; 施金元

显示项目 61-70 / 209 (共21页)
<< < 2 3 4 5 6 7 8 9 10 11 > >>
每页显示[10|25|50]项目